Quantum-Si to Showcase Protein Sequencing Technology at Festival of Genomics Boston

Quantum-Si will showcase its protein sequencing technology at the Festival of Genomics & Biodata Boston. Melissa Deck from Liberate Bio will present on the company's Platinum Pro instrument and NGPS technology, highlighting its potential in drug development through protein barcoding and multiplexed protein screening. The session is scheduled for June 24, 2025, at 12:00 PM EDT.

Quantum-Si Incorporated (Nasdaq: QSI), a proteomics technology company specializing in single-molecule detection, will present its innovative protein sequencing technology at the upcoming Festival of Genomics & Biodata Boston. The company will highlight its Platinum Pro instrument and Next-Gen Protein Sequencing™ (NGPS™) technology, demonstrating their potential in drug development through protein barcoding and multiplexed protein screening.

Melissa Deck, Director of Platform at Liberate Bio, will present "Precision Proteomics: Advancing Drug Development with Next-Gen Protein Sequencing™ (NGPS™)" on June 24, 2025, at 12:00 PM EDT. The session will take place at the Proteomics Stage and will feature key advancements in protein sequencing technology, including the introduction of single-molecule protein sequencing with NGPS™ on an accessible, benchtop platform. Deck will also discuss how protein barcoding can bridge the genome-to-phenotype gap, enhance proteomics, genomics, and therapeutic discovery, and enable efficient in vitro and in vivo screening in nucleic acid–LNP therapeutic development.

Quantum-Si's platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows, directly accessing dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si aims to accelerate proteomic discoveries and improve the way scientists study proteins.

The company's forward-looking statements include expectations regarding future performance, product development, and commercialization activities. However, it is essential to note that these statements involve significant risks and uncertainties, and actual results may differ materially from those discussed.

References:
[1] https://finance.yahoo.com/news/quantum-si-customer-showcase-protein-120000251.html
[2] https://www.marketscreener.com/quote/stock/QUANTUM-SI-INCORPORATED-123687657/news/Quantum-Si-Customer-to-Showcase-Protein-Barcoding-for-Nucleic-Acid-LNP-Therapeutic-Development-at-50262080/